Q3 2025 Haemonetics Corp Earnings Call Transcript
Key Points
- Haemonetics Corp (HAE) reported a 4% increase in third-quarter revenue on a reported basis, with adjusted earnings per share up 14%.
- The company is experiencing strong growth in its hospital business, with revenue up 24% on a reported basis and 12% organically.
- Haemonetics Corp (HAE) is gaining market share in the plasma segment, particularly in the US and Europe, through technology upgrades and new long-term agreements with BioLife and Grifols.
- The divestiture of the whole blood business is expected to align resources with higher-margin opportunities, contributing to improved profitability.
- The company achieved a record adjusted operating income margin of 25.7% in the third quarter, reflecting a 390-basis point increase year over year.
- Plasma revenue declined 9% in the quarter due to the planned CSL transition, impacting North America disposables revenue.
- The company is facing challenges in China, with significant cutbacks in reimbursement affecting the hemostasis management segment.
- Vascular closure growth was lower than expected due to competition in coronary and peripheral procedures.
- Haemonetics Corp (HAE) acknowledged falling short of ambitious targets in sensor-guided technologies and esophageal cooling markets.
- Free cash flow guidance was lowered due to increased working capital needs, particularly higher inventory levels.
Good day and welcome to the Haemonetics third quarter, fiscal year 2025 conference call and webcast. (Operator instructions)
I would like to turn the call over to Olga Guyette, Vice President, Investor Relations and Treasury. Please go ahead.
Good morning, everyone. Thank you for joining us for Haemonetics third-quarter, fiscal year 2025 conference call and webcast.
I'm joined today by Chris Simon, our CEO and James D Arecca, our CFO. This morning, we posted our third quarter and year-to-date fiscal year 2025 results to our investor relations website along with our updated fiscal year 2025 guidance.
As usual, a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise and exclude the impact of currency fluctuation, acquisitions and investitures. We'll also refer to other non-GAAP financial measures to help investors understand human addicts ongoing business performance.
Please note that these measures exclude certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
